Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC Thursday, April 11, 2024, 12:00 PM–1:00 PM ET Webinar presenter Zin Htway, PhD Supervisor and Operations Manager, Anatomic Pathology as HCA, Los Robles Hospital and Medical Center, will discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC. Dr. Htway will review the potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC and explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC.
Read More »CAP TODAY WEBINARS
Combining Clinical Signs and Symptoms with Histopathology for Definitive Diagnosis of Idiopathic Multicentric Castleman Disease (iMCD)
Empowering Pathology Partnerships for Growth & Rewards with GoPath
Implementation of an FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients
Webinar presenters Alexander Craig MacKinnon, Jr, MD, PhD, Professor, Department of Pathology, University of Alabama at Birmingham, Darshan Chandrashekar, PhD, Assistant Professor, Department of Pathology-Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham, and Shuko Harada, MD, Professor, Department of Pathology-Genomic Diagnostics and Bioinformatics, University of Alabama at Birmingham, discuss rapid biomarker identification and how it promises more comprehensive approaches.
Read More »Diagnostic Stewardship in Acute Infectious Gastroenteritis: What Can Real-World Data Tell Us?
Webinar presenter Ferric C. Fang, MD, discusses the relationship between diagnostic test method and clinical outcomes, challenges in diagnostic testing for acute infectious gastroenteritis, how real-world data shows us the impact diagnostic testing can have on clinical outcomes, and the role of diagnostic stewardship in optimizing diagnostic testing for gastroenteritis.
Read More »Post-Transplant Viral Infections: Challenges with Clinical Management
Webinar presenters Elena Beam, MD, and Joseph Yao, MD, discuss the need for standardization in post-transplant diagnostics with emphasis on Epstein-Barr virus (EBV), BK virus (BKV), and CMV.
HER2 Testing in Metastatic Colorectal Cancer (mCRC)
Webinar presenters Jaclyn Hechtman, MD, and John Marshall, MD, discuss how HER2 testing in mCRC opens a powerful new window for patients, testing methodology to identify HER2+ mCRC, a new treatment for patients with HER2+ mCRC, the importance of testing for HER2 in mCRC, and the efficacy and safety data from the MOUNTAINEER trial.
Recommendations for reporting race free estimated glomerular filtration rate
Webinar presenter Greg Miller, PhD, Professor of Pathology, Director of Pathology Information Systems, Co-Director of Clinical Chemistry, Virginia Commonwealth University Health System, Richmond, Virginia, discusses why all labs should be using the 2021 CKD-EPI equations for eGFR from creatinine, how the new equations will standardize laboratory practice to improve patient care, and when and how follow up testing for CKD should be performed.
Rapid Lung NGS is enabling clinicians and reducing biomarker testing costs
Webinar presenters Lauren Ritterhouse, MD, PhD, and Ibiayi Dagogo-Jack, MD, discuss consolidating NSCLC biomarker testing into a rapid lung NGS program, what the positive implications are for oncologists and for patients with cancer, and how the new consolidated workflow saves time and resources.
IVD vs. RUO–Is Your Laboratory Relying on the Right Products? What you need to know to protect patients and your laboratory.
Webinar presenter Sebastian Gromminger, PhD, Strategic Expert in the field of in-vitro diagnostics with a focus on molecular genetic diagnostics, Consultant for the approval of in-vitro diagnostics, Johner Institut GmbH, discusses what the “Research Use Only” (RUO) label means and its consequences for medical laboratories, manufacturers, and patients.
Measurable Residual Disease Testing in Acute Lymphoblastic Leukemia: Testing, Sampling, and Guidelines
Webinar presenter Rashmi Kanagal-Shamanna, MD, Associate Professor, Department of Hematopathology, Director, Molecular Diagnostics Laboratory-Microarray, discusses the importance of MRD testing in ALL MRD testing methods, guideline recommendations, and special considerations, optimal sampling for MRD testing, and patient cases that demonstrate the use of MRD testing in ALL. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast October 25, 2022.
Enabling precision oncology care through collaboration: testing before treating ERBB2/HER2 mutations in mNSCLC
Webinar presenters Narjust Duma, MD, Dana-Farber Cancer Institute, and Salvatore Priore, MD, PhD, University of Pennsylvania, Perelman School of Medicine, discuss the rapidly evolving biomarker landscape in metastatic non-small cell lung cancer (NSCLC), with the focus on emerging ERBB2/HER2 mutations, including exon 20 insertions. The oncologist and pathologist speakers will discuss their roles within the context of a multidisciplinary team to enable precision oncology care. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast October 19, 2022.
Optimizing the management of patients with solid tumors using a tumor-informed approach for molecular residual disease assessment and monitoring
Webinar presenters Noam Z. Drazin, MD, Medical Oncologist, Cedars Sinai Medical Center, and Gregory Botta, MD, PhD, Medical Oncologist-Associate Professor of Medicine, UC San Diego Health, discuss the rapidly evolving role of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and treatment response monitoring. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast October 13, 2022.
Next-Generation Sequencing: An Emerging Technique for Measurable Residual Disease (MRD) Detection inAcute Myeloid Leukemia
Webinar presenter Jerald Radich, MD, Clinical Research Division, Kurt Enslein Endowed Chair, Fred Hutchinson Cancer Center, discusses the latest research on MRD in acute myeloid leukemia, techniques for MRD detection, the implications of MRD in disease progression, prognosis and therapy selection, challenges of traditional MRD testing methods, the medical guidelines, and why NGS is emerging as a powerful technique for MRD detection. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast September 27, 2022.
Methylation Analysis: A new approach to sarcoma classification
Webinar presenters Andreas von Deimling, MD, Department of Neuropathology, Institute of Pathology, University Heidelberg, and Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and Christian Kölsche, MD, Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, discuss sarcoma classification by DNA methylation profiling, principles of methylation-based tumor classification, approaches to sarcomas with methylation analysis, and practical examples and outlook of accessing the tool. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast July 20, 2022.
Post-transplant viral load monitoring: the importance of standardization and commutability of diagnostic methods
Webinar presenters Steve Miller, MD, PhD, University of California San Francisco, and Joseph Yao, MD, Mayo Clinic, Rochester, Minnesota, discuss the need for standardization in post-transplant diagnostics with emphasis on Epstein-Barr virus (EBV) and BK virus (BKV), how this can be achieved and how improvements in laboratory testing can potentially translate into better patient care, and the impact of COVID-19 on transplant diagnostics and laboratory testing and what this means for patients and for the laboratory. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast November 5, 2020.
Read More »